Trial
NCT04804709
Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Columbia University
Collaborators
Focused Ultrasound Foundation
Condition
Diffuse Intrinsic Pontine Glioma
Intervention
Panobinostat 15 MG
Why stopped
FDA withdrew approval of the new drug application (NDA) for panobinostat as of March 24, 2022 because it was not feasible for the company to complete the required postmarketing clinical trials.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-08